In a trial in Huntington’s disease, the Pfizer PDE10A inhibitor MP-10 did not show efficacy on the primary endpoints but was found to produce consistent and dose-dependent improvements in a quantitative motor (Q-motor) assessment [45]. Here, PDE10A is linked to juvenile Huntington disease.